Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.
Coming Soon: More Targeted Oral Asthma Therapies
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Asthma remains a difficult disease to treat and control, with a large portion of the patient population not receiving adequate treatment options. But next-generation therapies are targeting this inflammation by being more targeted, getting at the root of the pathways that play a larger role in the disease. Bob Baltera, chief executive officer of Amira Pharmaceuticals, tells host Bruce Japsen about developments in more targeted therapies.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Level Up Your Skills: Tailoring Management of HF
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?